US Brachial Plexus Injury Market

ID: MRFR/Pharma/18343-HCR
100 Pages
Satyendra Maurya
Last Updated: May 13, 2026
US Brachial Plexus Injury Market Research Report By Type of Injury (Avulsion, Rupture, Neuroma, Stretch), By Treatment Type (Surgical Treatment, Physical Therapy, Medication, Rehabilitation), By Patient Demographics (Infants, Adults, Elderly) and By Diagnostic Method (Electromyography, Ultrasound, MRI) - Growth & Industry Forecast 2025 To 2035
US Brachial Plexus Injury Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.88%
2024 Market Size$ 168 Million
2025 Market Size$ 181.24 Million
2035 Market Size$ 387 Million
Key Players
Medtronic
Stryker
Johnson & Johnson
Boston Scientific
Smith & Nephew
Zimmer Biomet
Trends
  • Advancements in Surgical Techniques
  • Growth of Rehabilitation Services
  • Increased Focus on Patient Education
Opportunities
  • Growing Awareness and Advocacy
  • Technological Innovations in Treatment
  • Rising Incidence of Brachial Plexus Injuries
Summary Table of Contents Segmentation Download PDF
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Construction, BY Type of Injury (USD Million) | |
      1. 4.1.1 Avulsion | |
      2. 4.1.2 Rupture | |
      3. 4.1.3 Neuroma | |
      4. 4.1.4 Stretch |
    2. 4.2 Construction, BY Treatment Type (USD Million) | |
      1. 4.2.1 Surgical Treatment | |
      2. 4.2.2 Physical Therapy | |
      3. 4.2.3 Medication | |
      4. 4.2.4 Rehabilitation |
    3. 4.3 Construction, BY Patient Demographics (USD Million) | |
      1. 4.3.1 Infants | |
      2. 4.3.2 Adults | |
      3. 4.3.3 Elderly |
    4. 4.4 Construction, BY Diagnostic Method (USD Million) | |
      1. 4.4.1 Electromyography | |
      2. 4.4.2 Ultrasound | |
      3. 4.4.3 MRI 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Construction | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Medtronic (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Stryker (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Johnson & Johnson (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Boston Scientific (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Smith & Nephew (GB) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Zimmer Biomet (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 NuVasive (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Aesculap (DE) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Orthofix (US) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 US MARKET ANALYSIS BY TYPE OF INJURY |
    6. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE |
    7. 6.4 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    8. 6.5 US MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    9. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION |
    10. 6.7 RESEARCH PROCESS OF MRFR |
    11. 6.8 DRO ANALYSIS OF CONSTRUCTION |
    12. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION |
    13. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION |
    14. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION |
    15. 6.12 CONSTRUCTION, BY TYPE OF INJURY, 2024 (% SHARE) |
    16. 6.13 CONSTRUCTION, BY TYPE OF INJURY, 2024 TO 2035 (USD Million) |
    17. 6.14 CONSTRUCTION, BY TREATMENT TYPE, 2024 (% SHARE) |
    18. 6.15 CONSTRUCTION, BY TREATMENT TYPE, 2024 TO 2035 (USD Million) |
    19. 6.16 CONSTRUCTION, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE) |
    20. 6.17 CONSTRUCTION, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million) |
    21. 6.18 CONSTRUCTION, BY DIAGNOSTIC METHOD, 2024 (% SHARE) |
    22. 6.19 CONSTRUCTION, BY DIAGNOSTIC METHOD, 2024 TO 2035 (USD Million) |
    23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    24. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    25. 7.2 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE OF INJURY, 2025-2035 (USD Million) | |
      2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
      3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) | |
      4. 7.2.4 BY DIAGNOSTIC METHOD, 2025-2035 (USD Million) |
    26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.3.1 |
    27. 7.4 ACQUISITION/PARTNERSHIP | |

US Brachial Plexus Injury Market Segmentation

US Brachial Plexus Injury Market By Type of Injury (USD Million, 2025-2035)

  • Avulsion
  • Rupture
  • Neuroma
  • Stretch

US Brachial Plexus Injury Market By Treatment Type (USD Million, 2025-2035)

  • Surgical Treatment
  • Physical Therapy
  • Medication
  • Rehabilitation

US Brachial Plexus Injury Market By Patient Demographics (USD Million, 2025-2035)

  • Infants
  • Adults
  • Elderly

US Brachial Plexus Injury Market By Diagnostic Method (USD Million, 2025-2035)

  • Electromyography
  • Ultrasound
  • MRI

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.